Sponsor or institution
Clinical trials and research at Cogent Biosciences, Inc.
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Cogent Biosciences, Inc. that are recruiting, at sites in 25 countries (most in United States (4), Australia (2), Canada (2)). By phase: Phase 1 (2), Phase 3 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 25Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Mutant-selective inhibitor CGT6297 in advanced solid tumors with PIK3CA mutations | Phase 1 | Scottsdale, Arizona and 11 other locations | Recruiting | Feb 3, 2026 |
| Selective ERBB2 inhibitor CGT4255 for adults with ERBB2-altered advanced solid tumors | Phase 1 | Scottsdale, Arizona and 14 other locations | Recruiting | Jan 23, 2026 |
| (Peak) CGT9486 plus Sunitinib vs Sunitinib in advanced or metastatic GIST | Phase 3 | Birmingham, Alabama and 125 other locations | Recruiting | Jan 26, 2022 |
| Bezuclastinib treatment for advanced systemic mastocytosis | Phase 2 | Birmingham, Alabama and 41 other locations | Recruiting | Aug 9, 2021 |
All recruiting trials (4)
-
Mutant-selective inhibitor CGT6297 in advanced solid tumors with PIK3CA mutations
This phase 1 study tests CGT6297 to see if it is safe and tolerable, and to get an early sense of activity, in adults with advanced solid tumors that have PIK3CA mutations.
-
Selective ERBB2 inhibitor CGT4255 for adults with ERBB2-altered advanced solid tumors
This trial tests a targeted drug called CGT4255 in adults with advanced solid tumors that have ERBB2 (HER2) changes to see if it is safe and shows anti-tumor activity.
-
(Peak) CGT9486 plus Sunitinib vs Sunitinib in advanced or metastatic GIST
This study tests whether adding CGT9486 to sunitinib helps people with advanced or metastatic GIST who have already tried other treatments.
-
Bezuclastinib treatment for advanced systemic mastocytosis
This study is testing a new treatment called bezuclastinib to see if it can help people with advanced systemic mastocytosis feel better and manage their symptoms.
Quick answers
How many clinical trials run by Cogent Biosciences, Inc. are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 25 countries. The most sites are in United States (4 trials), Australia (2 trials), Canada (2 trials), France (2 trials), Germany (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 3: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.